BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Parkes GC, Brostoff J, Whelan K, Sanderson JD. Gastrointestinal microbiota in irritable bowel syndrome: their role in its pathogenesis and treatment. Am J Gastroenterol. 2008;103:1557-1567. [PMID: 18513268 DOI: 10.1111/j.1572-0241.2008.01869.x] [Cited by in Crossref: 104] [Cited by in F6Publishing: 95] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Tazzyman S, Richards N, Trueman AR, Evans AL, Grant VA, Garaiova I, Plummer SF, Williams EA, Corfe BM. Vitamin D associates with improved quality of life in participants with irritable bowel syndrome: Outcomes from a pilot trial. BMJ Open Gastroenterol. 2015;2:e000052. [PMID: 26719813 DOI: 10.1136/bmjgast-2015-000052] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
2 Shimozato A, Sasaki M, Ogasawara N, Funaki Y, Ebi M, Goto C, Koikeda S, Joh T, Kasugai K. Transglucosidase improves the bowel movements in type 2 diabetes mellitus patients: A preliminary randomized double-blind, placebo-controlled study. United European Gastroenterol J 2017;5:898-907. [PMID: 29026604 DOI: 10.1177/2050640617692268] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
3 Jeffery P, McDonald V, Tippett E, McGuckin M. Ghrelin in gastrointestinal disease. Mol Cell Endocrinol. 2011;340:35-43. [PMID: 21458525 DOI: 10.1016/j.mce.2011.03.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
4 Simrén M, Barbara G, Flint HJ, Spiegel BM, Spiller RC, Vanner S, Verdu EF, Whorwell PJ, Zoetendal EG; Rome Foundation Committee. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut 2013;62:159-76. [PMID: 22730468 DOI: 10.1136/gutjnl-2012-302167] [Cited by in Crossref: 513] [Cited by in F6Publishing: 429] [Article Influence: 57.0] [Reference Citation Analysis]
5 Soares RL. Irritable bowel syndrome: a clinical review. World J Gastroenterol. 2014;20:12144-12160. [PMID: 25232249 DOI: 10.3748/wjg.v20.i34.12144] [Cited by in CrossRef: 90] [Cited by in F6Publishing: 72] [Article Influence: 15.0] [Reference Citation Analysis]
6 Costabile A, Santarelli S, Claus SP, Sanderson J, Hudspith BN, Brostoff J, Ward JL, Lovegrove A, Shewry PR, Jones HE. Effect of breadmaking process on in vitro gut microbiota parameters in irritable bowel syndrome. PLoS One. 2014;9:e111225. [PMID: 25356771 DOI: 10.1371/journal.pone.0111225] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 3.7] [Reference Citation Analysis]
7 Chang JY, Talley NJ. An update on irritable bowel syndrome: from diagnosis to emerging therapies. Curr Opin Gastroenterol. 2011;27:72-78. [PMID: 21099429 DOI: 10.1097/mog.0b013e3283414065] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
8 Choi SC, Kim BJ, Rhee PL, Chang DK, Son HJ, Kim JJ, Rhee JC, Kim SI, Han YS, Sim KH. Probiotic Fermented Milk Containing Dietary Fiber Has Additive Effects in IBS with Constipation Compared to Plain Probiotic Fermented Milk. Gut Liver. 2011;5:22-28. [PMID: 21461068 DOI: 10.5009/gnl.2011.5.1.22] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
9 Bolino CM, Bercik P. Pathogenic factors involved in the development of irritable bowel syndrome: focus on a microbial role. Infect Dis Clin North Am. 2010;24:961-975, ix. [PMID: 20937460 DOI: 10.1016/j.idc.2010.07.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
10 Shavakhi A, Minakari M, Farzamnia S, Peykar MS, Taghipour G, Tayebi A, Hashemi H, Shavakhi S. The effects of multi-strain probiotic compound on symptoms and quality-of-life in patients with irritable bowel syndrome: A randomized placebo-controlled trial. Adv Biomed Res. 2014;3:140. [PMID: 25161987 DOI: 10.4103/2277-9175.135157] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
11 Lyra A, Rinttilä T, Nikkilä J, Krogius-Kurikka L, Kajander K, Malinen E, Mättö J, Mäkelä L, Palva A. Diarrhoea-predominant irritable bowel syndrome distinguishable by 16S rRNA gene phylotype quantification. World J Gastroenterol. 2009;15:5936-5945. [PMID: 20014457 DOI: 10.3748/wjg.15.5936] [Cited by in CrossRef: 102] [Cited by in F6Publishing: 101] [Article Influence: 9.3] [Reference Citation Analysis]
12 Agostini S, Goubern M, Tondereau V, Salvador-Cartier C, Bezirard V, Lévèque M, Keränen H, Theodorou V, Bourdu-Naturel S, Goupil-Feuillerat N. A marketed fermented dairy product containing Bifidobacterium lactis CNCM I-2494 suppresses gut hypersensitivity and colonic barrier disruption induced by acute stress in rats. Neurogastroenterol Motil. 2012;24:376-e172. [PMID: 22272920 DOI: 10.1111/j.1365-2982.2011.01865.x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 59] [Article Influence: 6.9] [Reference Citation Analysis]
13 Tremellen K, Pearce K. Dysbiosis of Gut Microbiota (DOGMA)--a novel theory for the development of Polycystic Ovarian Syndrome. Med Hypotheses. 2012;79:104-112. [PMID: 22543078 DOI: 10.1016/j.mehy.2012.04.016] [Cited by in Crossref: 84] [Cited by in F6Publishing: 71] [Article Influence: 9.3] [Reference Citation Analysis]
14 Lian Q, Ding H, Zhu H, Zhang C, Yu S, Jie H, Zhang Y, Wu B, Liang G, Zhang G, Sun H. Study of Jianpi Mixture on Intestinal Microbiota of Diarrhea Irritable Bowel Syndrome Mice. Evid Based Complement Alternat Med 2020;2020:5241308. [PMID: 32419810 DOI: 10.1155/2020/5241308] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
15 Muniz LR, Knosp C, Yeretssian G. Intestinal antimicrobial peptides during homeostasis, infection, and disease. Front Immunol. 2012;3:310. [PMID: 23087688 DOI: 10.3389/fimmu.2012.00310] [Cited by in Crossref: 97] [Cited by in F6Publishing: 81] [Article Influence: 10.8] [Reference Citation Analysis]
16 Valeur J, Småstuen MC, Knudsen T, Lied GA, Røseth AG. Exploring Gut Microbiota Composition as an Indicator of Clinical Response to Dietary FODMAP Restriction in Patients with Irritable Bowel Syndrome. Dig Dis Sci 2018;63:429-36. [DOI: 10.1007/s10620-017-4893-3] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 11.7] [Reference Citation Analysis]
17 Sayuk GS, Gyawali CP. Irritable bowel syndrome: modern concepts and management options. Am J Med. 2015;128:817-827. [PMID: 25731138 DOI: 10.1016/j.amjmed.2015.01.036] [Cited by in Crossref: 34] [Cited by in F6Publishing: 20] [Article Influence: 5.7] [Reference Citation Analysis]
18 Connell M, Shin A, James-Stevenson T, Xu H, Imperiale TF, Herron J. Systematic review and meta-analysis: Efficacy of patented probiotic, VSL#3, in irritable bowel syndrome. Neurogastroenterol Motil 2018;30:e13427. [PMID: 30069978 DOI: 10.1111/nmo.13427] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
19 Pinn DM, Aroniadis OC, Brandt LJ. Is Fecal Microbiota Transplantation the Answer for Irritable Bowel Syndrome? A Single-Center Experience. American Journal of Gastroenterology 2014;109:1831-2. [DOI: 10.1038/ajg.2014.295] [Cited by in Crossref: 59] [Cited by in F6Publishing: 51] [Article Influence: 8.4] [Reference Citation Analysis]
20 Karatay E, Utku ÖG. Serum resolvin D1 levels as a marker of inflammation in constipation dominant irritable bowel syndrome. Turk J Gastroenterol 2020;31:113-9. [PMID: 32141819 DOI: 10.5152/tjg.2020.19751] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
21 Okeke F, Roland BC, Mullin GE. The role of the gut microbiome in the pathogenesis and treatment of obesity. Glob Adv Health Med 2014;3:44-57. [PMID: 24891993 DOI: 10.7453/gahmj.2014.018] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
22 Lee HJ, Choi JK, Ryu HS, Choi CH, Kang EH, Park KS, Min YW, Hong KS. Therapeutic Modulation of Gut Microbiota in Functional Bowel Disorders. J Neurogastroenterol Motil 2017;23:9-19. [PMID: 28049862 DOI: 10.5056/jnm16124] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 3.8] [Reference Citation Analysis]
23 Krogius-Kurikka L, Lyra A, Malinen E, Aarnikunnas J, Tuimala J, Paulin L, Mäkivuokko H, Kajander K, Palva A. Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers. BMC Gastroenterol 2009;9:95. [PMID: 20015409 DOI: 10.1186/1471-230X-9-95] [Cited by in Crossref: 175] [Cited by in F6Publishing: 117] [Article Influence: 14.6] [Reference Citation Analysis]
24 Whelan K, Myers CE. Safety of probiotics in patients receiving nutritional support: a systematic review of case reports, randomized controlled trials, and nonrandomized trials. Am J Clin Nutr. 2010;91:687-703. [PMID: 20089732 DOI: 10.3945/ajcn.2009.28759] [Cited by in Crossref: 106] [Cited by in F6Publishing: 82] [Article Influence: 9.6] [Reference Citation Analysis]
25 Pinn DM, Aroniadis OC, Brandt LJ. Is fecal microbiota transplantation (FMT) an effective treatment for patients with functional gastrointestinal disorders (FGID)? Neurogastroenterol Motil. 2015;27:19-29. [PMID: 25424663 DOI: 10.1111/nmo.12479] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 7.7] [Reference Citation Analysis]
26 Porter CK, Gormley R, Tribble DR, Cash BD, Riddle MS. The Incidence and gastrointestinal infectious risk of functional gastrointestinal disorders in a healthy US adult population. Am J Gastroenterol 2011;106:130-8. [PMID: 20859264 DOI: 10.1038/ajg.2010.371] [Cited by in Crossref: 67] [Cited by in F6Publishing: 57] [Article Influence: 6.1] [Reference Citation Analysis]
27 Kelesidis T, Pothoulakis C. Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders. Therap Adv Gastroenterol. 2012;5:111-125. [PMID: 22423260 DOI: 10.1177/1756283x11428502] [Cited by in Crossref: 129] [Cited by in F6Publishing: 53] [Article Influence: 14.3] [Reference Citation Analysis]
28 Halliez MC, Buret AG. Extra-intestinal and long term consequences of Giardia duodenalis infections. World J Gastroenterol 2013;19:8974-85. [PMID: 24379622 DOI: 10.3748/wjg.v19.i47.8974] [Cited by in CrossRef: 195] [Cited by in F6Publishing: 159] [Article Influence: 27.9] [Reference Citation Analysis]
29 Shin CM, Kim N, Kim YS, Nam RH, Park JH, Lee DH, Seok YJ, Kim YR, Kim JH, Kim JM, Kim JS, Jung HC. Impact of Long-Term Proton Pump Inhibitor Therapy on Gut Microbiota in F344 Rats: Pilot Study. Gut Liver 2016;10:896-901. [PMID: 27458177 DOI: 10.5009/gnl15529] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
30 Agrawal A, Houghton LA, Morris J, Reilly B, Guyonnet D, Goupil Feuillerat N, Schlumberger A, Jakob S, Whorwell PJ. Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Alimentary Pharmacology & Therapeutics 2009;29:104-14. [DOI: 10.1111/j.1365-2036.2008.03853.x] [Cited by in Crossref: 187] [Cited by in F6Publishing: 143] [Article Influence: 15.6] [Reference Citation Analysis]
31 Fujiya M, Kohgo Y. Novel perspectives in probiotic treatment: the efficacy and unveiled mechanisms of the physiological functions. Clin J Gastroenterol 2010;3:117-27. [PMID: 26190117 DOI: 10.1007/s12328-010-0154-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
32 Pimentel M, Chang C. Inflammation and microflora. Gastroenterol Clin North Am. 2011;40:69-85. [PMID: 21333901 DOI: 10.1016/j.gtc.2010.12.010] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
33 Seo AY, Kim N, Oh DH. Abdominal bloating: pathophysiology and treatment. J Neurogastroenterol Motil 2013;19:433-53. [PMID: 24199004 DOI: 10.5056/jnm.2013.19.4.433] [Cited by in Crossref: 34] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
34 Yue YY, Fan XY, Zhang Q, Lu YP, Wu S, Wang S, Yu M, Cui CW, Sun ZR. Bibliometric analysis of subject trends and knowledge structures of gut microbiota. World J Clin Cases 2020;8:2817-32. [PMID: 32742991 DOI: 10.12998/wjcc.v8.i13.2817] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
35 Whelan K. Mechanisms and effectiveness of prebiotics in modifying the gastrointestinal microbiota for the management of digestive disorders. Proc Nutr Soc 2013;72:288-98. [PMID: 23680358 DOI: 10.1017/S0029665113001262] [Cited by in Crossref: 28] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
36 O'dwyer DD, Darville RL. Specific carbohydrate diet: irritable bowel syndrome patient case study. Nutrition & Food Science 2015;45:859-72. [DOI: 10.1108/nfs-05-2015-0056] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
37 Veiga P, Gallini CA, Beal C, Michaud M, Delaney ML, DuBois A, Khlebnikov A, van Hylckama Vlieg JE, Punit S, Glickman JN, Onderdonk A, Glimcher LH, Garrett WS. Bifidobacterium animalis subsp. lactis fermented milk product reduces inflammation by altering a niche for colitogenic microbes. Proc Natl Acad Sci U S A 2010;107:18132-7. [PMID: 20921388 DOI: 10.1073/pnas.1011737107] [Cited by in Crossref: 153] [Cited by in F6Publishing: 134] [Article Influence: 13.9] [Reference Citation Analysis]
38 Hong SN, Rhee PL. Unraveling the ties between irritable bowel syndrome and intestinal microbiota. World J Gastroenterol 2014;20:2470-81. [PMID: 24627584 DOI: 10.3748/wjg.v20.i10.2470] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 36] [Article Influence: 6.8] [Reference Citation Analysis]
39 Murata M, Sugimoto M, Otsuka T, Nishida A, Inatomi O, Bamba S, Andoh A. Successful Helicobacter pylori eradication therapy improves symptoms of chronic constipation. Helicobacter 2018;23. [DOI: 10.1111/hel.12543] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Clayton EM, Rea MC, Shanahan F, Quigley EMM, Kiely B, Ross RP, Hill C. Carriage of Clostridium difficile in outpatients with irritable bowel syndrome. J Med Microbiol 2012;61:1290-4. [PMID: 22580916 DOI: 10.1099/jmm.0.040568-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
41 Ohman L, Simrén M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol. 2010;7:163-173. [PMID: 20101257 DOI: 10.1038/nrgastro.2010.4] [Cited by in Crossref: 362] [Cited by in F6Publishing: 321] [Article Influence: 32.9] [Reference Citation Analysis]
42 El-Salhy M, Mazzawi T. Fecal microbiota transplantation for managing irritable bowel syndrome. Expert Rev Gastroenterol Hepatol. 2018;12:439-445. [PMID: 29493330 DOI: 10.1080/17474124.2018.1447380] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 10.3] [Reference Citation Analysis]
43 Di Stefano AFD, Radicioni MM, Vaccani A, Mazzetti A, Longo LM, Moro L. Pharmacokinetics and Safety of Rifamycin SV after Single and Multiple Doses of MMX® Modified Release Tablets in Healthy Male and Female Volunteers. Antibiotics (Basel) 2021;10:167. [PMID: 33562091 DOI: 10.3390/antibiotics10020167] [Reference Citation Analysis]
44 Zhang M, Yang XJ. Effects of a high fat diet on intestinal microbiota and gastrointestinal diseases. World J Gastroenterol. 2016;22:8905-8909. [PMID: 27833381 DOI: 10.3748/wjg.v22.i40.8905] [Cited by in CrossRef: 61] [Cited by in F6Publishing: 54] [Article Influence: 15.3] [Reference Citation Analysis]
45 Walk ST, Young VB. Emerging Insights into Antibiotic-Associated Diarrhea and Clostridium difficile Infection through the Lens of Microbial Ecology. Interdiscip Perspect Infect Dis 2008;2008:125081. [PMID: 19277109 DOI: 10.1155/2008/125081] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
46 Sachdeva S, Rawat AK, Reddy RS, Puri AS. Small intestinal bacterial overgrowth (SIBO) in irritable bowel syndrome: frequency and predictors. J Gastroenterol Hepatol. 2011;26 Suppl 3:135-138. [PMID: 21443727 DOI: 10.1111/j.1440-1746.2011.06654.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 4.3] [Reference Citation Analysis]
47 Benno P, Norin E, Midtvedt T, Hellström PM. Therapeutic potential of an anaerobic cultured human intestinal microbiota, ACHIM, for treatment of IBS. Best Pract Res Clin Gastroenterol 2019;40-41:101607. [PMID: 31594647 DOI: 10.1016/j.bpg.2019.03.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
48 Shukla R, Ghoshal U, Dhole TN, Ghoshal UC. Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis. Dig Dis Sci. 2015;60:2953-2962. [PMID: 25784074 DOI: 10.1007/s10620-015-3607-y] [Cited by in Crossref: 73] [Cited by in F6Publishing: 59] [Article Influence: 12.2] [Reference Citation Analysis]
49 Guyonnet D, Schlumberger A, Mhamdi L, Jakob S, Chassany O. Fermented milk containing Bifidobacterium lactis DN-173 010 improves gastrointestinal well-being and digestive symptoms in women reporting minor digestive symptoms: a randomised, double-blind, parallel, controlled study. Br J Nutr. 2009;102:1654-1662. [PMID: 19622191 DOI: 10.1017/s0007114509990882] [Cited by in Crossref: 58] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
50 Ghoshal UC, Shukla R, Ghoshal U, Gwee KA, Ng SC, Quigley EM. The gut microbiota and irritable bowel syndrome: friend or foe? Int J Inflam. 2012;2012:151085. [PMID: 22577594 DOI: 10.1155/2012/151085] [Cited by in Crossref: 85] [Cited by in F6Publishing: 79] [Article Influence: 9.4] [Reference Citation Analysis]
51 Staudacher HM, Whelan K, Irving PM, Lomer MC. Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome. J Hum Nutr Diet. 2011;24:487-495. [PMID: 21615553 DOI: 10.1111/j.1365-277x.2011.01162.x] [Cited by in Crossref: 277] [Cited by in F6Publishing: 91] [Article Influence: 27.7] [Reference Citation Analysis]
52 Andrews CN, Griffiths TA, Kaufman J, Vergnolle N, Surette MG, Rioux KP. Mesalazine (5-aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2011;34:374-383. [PMID: 21671966 DOI: 10.1111/j.1365-2036.2011.04732.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 55] [Article Influence: 6.5] [Reference Citation Analysis]
53 Chang JY, Talley NJ. Current and emerging therapies in irritable bowel syndrome: from pathophysiology to treatment. Trends Pharmacol Sci. 2010;31:326-334. [PMID: 20554042 DOI: 10.1016/j.tips.2010.04.008] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
54 Oh JH, Jang YS, Kang D, Chang DK, Min YW. Efficacy and Safety of New Lactobacilli Probiotics for Unconstipated Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. Nutrients. 2019;11. [PMID: 31783597 DOI: 10.3390/nu11122887] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
55 Hellström PM. Pathophysiology of the irritable bowel syndrome - Reflections of today. Best Pract Res Clin Gastroenterol 2019;40-41:101620. [PMID: 31594651 DOI: 10.1016/j.bpg.2019.05.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
56 Yan F, Polk DB. Probiotics: progress toward novel therapies for intestinal diseases. Curr Opin Gastroenterol 2010;26:95-101. [PMID: 19952741 DOI: 10.1097/MOG.0b013e328335239a] [Cited by in Crossref: 65] [Cited by in F6Publishing: 20] [Article Influence: 5.9] [Reference Citation Analysis]
57 Michail S, Kenche H. Gut microbiota is not modified by Randomized, Double-blind, Placebo-controlled Trial of VSL#3 in Diarrhea-predominant Irritable Bowel Syndrome. Probiotics Antimicrob Proteins. 2011;3:1-7. [PMID: 22247743 DOI: 10.1007/s12602-010-9059-y] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 10.0] [Reference Citation Analysis]
58 Barrett JS. Extending our knowledge of fermentable, short-chain carbohydrates for managing gastrointestinal symptoms. Nutr Clin Pract. 2013;28:300-306. [PMID: 23614962 DOI: 10.1177/0884533613485790] [Cited by in Crossref: 33] [Cited by in F6Publishing: 22] [Article Influence: 4.1] [Reference Citation Analysis]
59 Salonen A, de Vos WM, Palva A. Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives. Microbiology. 2010;156:3205-3215. [PMID: 20705664 DOI: 10.1099/mic.0.043257-0] [Cited by in Crossref: 168] [Cited by in F6Publishing: 145] [Article Influence: 15.3] [Reference Citation Analysis]
60 Coudeyras S, Forestier C. Microbiote et probiotiques : impact en santé humaine. Can J Microbiol 2010;56:611-50. [DOI: 10.1139/w10-052] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
61 Cabré E. Clinical Nutrition University: Nutrition in the prevention and management of irritable bowel syndrome, constipation and diverticulosis. e-SPEN, the European e-Journal of Clinical Nutrition and Metabolism 2011;6:e85-95. [DOI: 10.1016/j.eclnm.2011.01.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
62 Parkes GC, Rayment NB, Hudspith BN, Petrovska L, Lomer MC, Brostoff J, Whelan K, Sanderson JD. Distinct microbial populations exist in the mucosa-associated microbiota of sub-groups of irritable bowel syndrome. Neurogastroenterol Motil. 2012;24:31-39. [PMID: 22070725 DOI: 10.1111/j.1365-2982.2011.01803.x] [Cited by in Crossref: 134] [Cited by in F6Publishing: 113] [Article Influence: 13.4] [Reference Citation Analysis]
63 Gwee KA, Bak YT, Ghoshal UC, Gonlachanvit S, Lee OY, Fock KM, Chua AS, Lu CL, Goh KL, Kositchaiwat C, Makharia G, Park HJ, Chang FY, Fukudo S, Choi MG, Bhatia S, Ke M, Hou X, Hongo M; Asian Neurogastroenterology and Motility Association. Asian consensus on irritable bowel syndrome. J Gastroenterol Hepatol. 2010;25:1189-1205. [PMID: 20594245 DOI: 10.1111/j.1440-1746.2010.06353.x] [Cited by in Crossref: 113] [Cited by in F6Publishing: 102] [Article Influence: 10.3] [Reference Citation Analysis]
64 Ghoshal U, Shukla R, Srivastava D, Ghoshal UC. Irritable Bowel Syndrome, Particularly the Constipation-Predominant Form, Involves an Increase in Methanobrevibacter smithii, Which Is Associated with Higher Methane Production. Gut Liver 2016;10:932-8. [PMID: 27458176 DOI: 10.5009/gnl15588] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 9.8] [Reference Citation Analysis]
65 Öhman L, Törnblom H, Simrén M. Crosstalk at the mucosal border: importance of the gut microenvironment in IBS. Nat Rev Gastroenterol Hepatol 2015;12:36-49. [DOI: 10.1038/nrgastro.2014.200] [Cited by in Crossref: 106] [Cited by in F6Publishing: 94] [Article Influence: 15.1] [Reference Citation Analysis]
66 Staudacher HM, Lomer MC, Anderson JL, Barrett JS, Muir JG, Irving PM, Whelan K. Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome. J Nutr. 2012;142:1510-1518. [PMID: 22739368 DOI: 10.3945/jn.112.159285] [Cited by in Crossref: 313] [Cited by in F6Publishing: 239] [Article Influence: 34.8] [Reference Citation Analysis]
67 Liu Y, Song X, Zhou H, Zhou X, Xia Y, Dong X, Zhong W, Tang S, Wang L, Wen S, Xiao J, Tang L. Gut Microbiome Associates With Lipid-Lowering Effect of Rosuvastatin in Vivo. Front Microbiol 2018;9:530. [PMID: 29623075 DOI: 10.3389/fmicb.2018.00530] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 11.3] [Reference Citation Analysis]
68 Ringel-Kulka T. Targeting the intestinal microbiota in the pediatric population: a clinical perspective. Nutr Clin Pract 2012;27:226-34. [PMID: 22402406 DOI: 10.1177/0884533612439895] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
69 Lee YJ, Park KS. Irritable bowel syndrome: emerging paradigm in pathophysiology. World J Gastroenterol 2014;20:2456-69. [PMID: 24627583 DOI: 10.3748/wjg.v20.i10.2456] [Cited by in CrossRef: 77] [Cited by in F6Publishing: 56] [Article Influence: 12.8] [Reference Citation Analysis]
70 Pittayanon R, Lau JT, Yuan Y, Leontiadis GI, Tse F, Surette M, Moayyedi P. Gut Microbiota in Patients With Irritable Bowel Syndrome-A Systematic Review.Gastroenterology. 2019;157:97-108. [PMID: 30940523 DOI: 10.1053/j.gastro.2019.03.049] [Cited by in Crossref: 129] [Cited by in F6Publishing: 108] [Article Influence: 64.5] [Reference Citation Analysis]
71 McKernan DP, Fitzgerald P, Dinan TG, Cryan JF. The probiotic Bifidobacterium infantis 35624 displays visceral antinociceptive effects in the rat. Neurogastroenterol Motil. 2010;22:1029-1035, e268. [PMID: 20518856 DOI: 10.1111/j.1365-2982.2010.01520.x] [Cited by in Crossref: 117] [Cited by in F6Publishing: 111] [Article Influence: 10.6] [Reference Citation Analysis]
72 El-Salhy M, Hausken T, Hatlebakk JG. Increasing the Dose and/or Repeating Faecal Microbiota Transplantation (FMT) Increases the Response in Patients with Irritable Bowel Syndrome (IBS). Nutrients. 2019;11. [PMID: 31238507 DOI: 10.3390/nu11061415] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
73 Sundin J, Öhman L, Simrén M. Understanding the Gut Microbiota in Inflammatory and Functional Gastrointestinal Diseases. Psychosom Med 2017;79:857-67. [PMID: 28422780 DOI: 10.1097/PSY.0000000000000470] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 8.7] [Reference Citation Analysis]
74 Alexea O, Bacarea V, Piqué N. The combination of oligo- and polysaccharides and reticulated protein for the control of symptoms in patients with irritable bowel syndrome: Results of a randomised, placebo-controlled, double-blind, parallel group, multicentre clinical trial. United European Gastroenterol J 2016;4:455-65. [PMID: 27403313 DOI: 10.1177/2050640615615050] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
75 Parkes GC, Sanderson JD, Whelan K. Treating irritable bowel syndrome with probiotics: the evidence. Proc Nutr Soc. 2010;69:187-194. [PMID: 20236566 DOI: 10.1017/s002966511000011x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
76 Lee SH, Kim KN, Kim KM, Joo NS. Irritable Bowel Syndrome May Be Associated with Elevated Alanine Aminotransferase and Metabolic Syndrome. Yonsei Med J 2016;57:146-52. [PMID: 26632395 DOI: 10.3349/ymj.2016.57.1.146] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 3.6] [Reference Citation Analysis]
77 Lee SH, Cho DY, Lee SH, Han KS, Yang SW, Kim JH, Lee SH, Kim SM, Kim KN. A Randomized Clinical Trial of Synbiotics in Irritable Bowel Syndrome: Dose-Dependent Effects on Gastrointestinal Symptoms and Fatigue. Korean J Fam Med 2019;40:2-8. [PMID: 30360032 DOI: 10.4082/kjfm.17.0064] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
78 Benjak Horvat I, Gobin I, Kresović A, Hauser G. How can probiotic improve irritable bowel syndrome symptoms? WJGS 2021;13:923-40. [DOI: 10.4240/wjgs.v13.i9.923] [Reference Citation Analysis]
79 Salzman NH. Paneth cell defensins and the regulation of the microbiome: détente at mucosal surfaces. Gut Microbes 2010;1:401-6. [PMID: 21468224 DOI: 10.4161/gmic.1.6.14076] [Cited by in Crossref: 67] [Cited by in F6Publishing: 54] [Article Influence: 7.4] [Reference Citation Analysis]
80 Wen W, Zhang H, Shen J, Wei L, Shen S. Fecal microbiota transplantation for patients with irritable bowel syndrome: A meta-analysis protocol. Medicine (Baltimore). 2018;97:e12661. [PMID: 30290648 DOI: 10.1097/md.0000000000012661] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
81 Pensabene L, Talarico V, Concolino D, Ciliberto D, Campanozzi A, Gentile T, Rutigliano V, Salvatore S, Staiano A, Di Lorenzo C, Graziano F, Palermo BV, Sanseviero M, Altomare F, Cozza E, Falvo A, Marseglia A, Gatta E, De Venuto D, Ripepi A, Turco R. Postinfectious Functional Gastrointestinal Disorders in Children: A Multicenter Prospective Study. The Journal of Pediatrics 2015;166:903-907.e1. [DOI: 10.1016/j.jpeds.2014.12.050] [Cited by in Crossref: 35] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
82 Lee SH, Cho DY, Joo NS, Kim KN. Effect of eradicating hydrogen-forming small intestinal bacterial overgrowth with rifaximin on body weight change. Medicine (Baltimore) 2019;98:e18396. [PMID: 31861004 DOI: 10.1097/MD.0000000000018396] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Wilson B, Rossi M, Dimidi E, Whelan K. Prebiotics in irritable bowel syndrome and other functional bowel disorders in adults: a systematic review and meta-analysis of randomized controlled trials. The American Journal of Clinical Nutrition 2019;109:1098-111. [DOI: 10.1093/ajcn/nqy376] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 17.0] [Reference Citation Analysis]
84 Lacy BE, Moreau JC. Diarrhea-predominant irritable bowel syndrome: Diagnosis, etiology, and new treatment considerations. J Am Assoc Nurse Pract 2016;28:393-404. [PMID: 27436200 DOI: 10.1002/2327-6924.12387] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
85 Cabré E. Irritable bowel syndrome: can nutrient manipulation help? Curr Opin Clin Nutr Metab Care. 2010;13:581-587. [PMID: 20531176 DOI: 10.1097/MCO.0b013e32833b6471] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
86 Cotton JA, Beatty JK, Buret AG. Host parasite interactions and pathophysiology in Giardia infections. Int J Parasitol. 2011;41:925-933. [PMID: 21683702 DOI: 10.1016/j.ijpara.2011.05.002] [Cited by in Crossref: 120] [Cited by in F6Publishing: 104] [Article Influence: 12.0] [Reference Citation Analysis]
87 Wang Y, Zheng F, Liu S, Luo H. Research Progress in Fecal Microbiota Transplantation as Treatment for Irritable Bowel Syndrome. Gastroenterol Res Pract 2019;2019:9759138. [PMID: 31885549 DOI: 10.1155/2019/9759138] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
88 Qin HY, Cheng CW, Tang XD, Bian ZX. Impact of psychological stress on irritable bowel syndrome. World J Gastroenterol. 2014;20:14126-14131. [PMID: 25339801 DOI: 10.3748/wjg.v20.i39.14126] [Cited by in CrossRef: 95] [Cited by in F6Publishing: 79] [Article Influence: 15.8] [Reference Citation Analysis]
89 Velasco-benítez CA, Ortíz-rivera CJ. ¿El antecedente de dengue está asociado a la presencia de Desórdenes Gastrointestinales Funcionales en Niños? Infect 2019;23:161. [DOI: 10.22354/in.v23i2.773] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
90 Pierre JF, Barlow-Anacker AJ, Erickson CS, Heneghan AF, Leverson GE, Dowd SE, Epstein ML, Kudsk KA, Gosain A. Intestinal dysbiosis and bacterial enteroinvasion in a murine model of Hirschsprung's disease. J Pediatr Surg 2014;49:1242-51. [PMID: 25092084 DOI: 10.1016/j.jpedsurg.2014.01.060] [Cited by in Crossref: 37] [Cited by in F6Publishing: 28] [Article Influence: 6.2] [Reference Citation Analysis]
91 El Amrousy D, Hassan S, El Ashry H, Yousef M, Hodeib H. Vitamin D supplementation in adolescents with irritable bowel syndrome: Is it useful? A randomized controlled trial. Saudi J Gastroenterol 2018;24:109-14. [PMID: 29637918 DOI: 10.4103/sjg.SJG_438_17] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 3.7] [Reference Citation Analysis]
92 Farup PG, Jacobsen M, Ligaarden SC, Rudi K. Probiotics, symptoms, and gut microbiota: what are the relations? A randomized controlled trial in subjects with irritable bowel syndrome. Gastroenterol Res Pract 2012;2012:214102. [PMID: 22899904 DOI: 10.1155/2012/214102] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
93 Lee KN, Lee OY. Intestinal microbiota in pathophysiology and management of irritable bowel syndrome. World J Gastroenterol. 2014;20:8886-8897. [PMID: 25083061 DOI: 10.3748/wjg.v20.i27.8886] [Cited by in F6Publishing: 28] [Reference Citation Analysis]
94 Li B, Liang L, Deng H, Guo J, Shu H, Zhang L. Efficacy and Safety of Probiotics in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis.Front Pharmacol. 2020;11:332. [PMID: 32317962 DOI: 10.3389/fphar.2020.00332] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 18.0] [Reference Citation Analysis]
95 Parkes GC. The Role of Probiotics in the Treatment of Irritable Bowel Syndrome. Bioactive Foods in Promoting Health. Elsevier; 2010. pp. 513-28. [DOI: 10.1016/b978-0-12-374938-3.00030-x] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]